The Prognostic Significance of TMSB4X in Glioma Patients.

OBJECTIVE: The goal of this study was to analyze in depth the importance of the thymosin beta 4 X-linked gene (TMSB4X) in the disease process of gliomas for the prediction of patient prognosis. METHODS: We explored the expression of TMSB4X by analyzing datasets from The Cancer Genome Atlas (TCGA) datasets and the Chinese Glioma Genome Atlas (CGGA). Tumor sample tissues and corresponding paracancerous tissues of glioma patients were collected, and TMSB4X expression in glioma tissues was analyzed using Real-Time PCR to investigate its prognostic significance in glioma patients. In addition, we have plotted the ROC curves for the survival rate, performed univariate and multivariate Cox analyses and constructed nomogram. Differential expression analyses were performed on the basis of median expression levels of the TMSB4X gene, and Intuitive graphical presentation and visualisation of the 403 proteins screened were carried out using the Cytoscape software platform. (version: 3.9.1). The top 50 core genes were then screened using the cyto Hubba algorithm, these genes were analyzed using The Gene Ontology Database (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). TCGA datasets was utilized for Gene Set Enrichment Analysis (GSEA) to obtain potential NF-κB-related pathways in gliomas. RESULTS: Independent prognostic analyses show that the TMSB4X gene was identified as an independent prognostic indicator for gliomas. In GOKEGG and GSEA analyses, the analyses indicate that TMSB4X may play a crucial role in glioma patients by up-regulating I-kappaB kinase/NF-kappaB signaling. In glioma patients, upregulation of the I-kappaB kinase and NF-kappaB signalling pathways plays a crucial role, which may be linked to CASP1. CONCLUSION: The findings showed that TMSB4X was identified as an potential independent risk factor in the prognosis of glioma patients, a finding that implies that TMSB4X has the potential to serve as a key biomarker for predicting the prognostic status of glioma patients.